Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine prospectively the effects of ketoconazole on the pharmacokinetics and electrocardiographic repolarization pharmacodynamics (corrected QT intervals) of terfenadine in men and women. DESIGN: Prospective cohort study with each subject serving as his or her own control. SETTING: Outpatient cardiology clinic and inpatient telemetry unit for monitoring period. PARTICIPANTS: Six healthy volunteers (four men and two women, aged 24 to 35 years) not taking any prescription or over-the-counter medications. INTERVENTION: After achieving a steady state while taking terfenadine (60 mg every 12 hours for 7 days), daily concomitant oral ketoconazole (200 mg every 12 hours) was added to the subjects' regimen. Pharmacokinetic profiles were obtained while subjects were taking terfenadine alone and after the addition of ketoconazole. Electrocardiograms were obtained at baseline, after 1 week of taking terfenadine alone, and at the time of the second pharmacokinetic profile after the addition of ketoconazole to the regimen. MAIN OUTCOME MEASURES: Terfenadine and its acid metabolite serum concentrations and corrected QT intervals. RESULTS: All subjects had detectable levels of unmetabolized terfenadine after the addition of ketoconazole, which was associated with QT prolongation. Only two of the six subjects could complete the entire course of ketoconazole coadministration. Four subjects received a shortened duration of ketoconazole therapy because of significant electrocardiographic repolarization abnormalities. There was a significant change in the area under the curve of the acid metabolite of terfenadine after the addition of ketoconazole administration. CONCLUSIONS: Ketoconazole alters the metabolism of terfenadine in normal men and women and results in the accumulation of unmetabolized parent drug, which is associated with significant prolongation of the corrected QT interval. This drug combination should be avoided.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Cerivastatin (Section 7.7) and terfenadine (Section 7.9) are metabolism- and interaction-dependent failures, in which a cytochrome P450 drug interaction rather than body size dictated the clinically decisive exposure.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [82]
In the citing paper
“Body-weight allometric scaling applied to total drug exposure would not have flagged a problem, because in monotherapy, preclinical species and humans both metabolize terfenadine efficiently, and parent plasma concentrations remain low.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [82]
In the citing paper
“(ii) the inversion of the parent-to-metabolite exposure ratio under CYP3A4 inhibition, converting a notionally safe prodrug system into a hERG-blockade liability;”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [82]
In the citing paper
“(iii) the absence of a routine preclinical assay for QT prolongation before ICH E14 and ICH S7B [82,83].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [82]
In the citing paper
“Reports of torsades de pointes and sudden death emerged when terfenadine was co-administered with CYP3A4 inhibitors such as ketoconazole, erythromycin, and the constituents of grapefruit juice, conditions under which parent terfenadine accumulated to concentrations sufficient to prolong QTc and trigger ventricular arrhythmia [82,83].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [82]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Torsades de Pointes Occurring in Association With Terfenadine Use
Monahan, B. P. (1990) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1990.03450210088038 · Cited by 667
Algra, A., Tijssen, J. G., Roelandt, J. R., Pool, J., & Lubsen, J. (1991) · Circulation · doi:10.1161/01.cir.83.6.1888 · Cited by 592
Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes.
Loose, D. S., Kan, P. B., Hirst, M. A., Marcus, R. A., & Feldman, D. (1983) · Journal of Clinical Investigation · doi:10.1172/jci110903 · Cited by 443
Honig, P. K., Woosley, R. L., Zamani, K., Conner, D. P., & Cantilena, L. R. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.135 · Cited by 367
Self-citationHigh affinity inhibition of Ca(2+)-dependent K+ channels by cytochrome P-450 inhibitors.
Alvarez, J., Montero, M., & Garcia-Sancho, J. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)49767-6 · Cited by 281
Pharmacokinetics and biotransformation studies of terfenadine in man.
Garteiz, D. A., Hook, R. H., Walker, B. J., & Okerholm, R. A. (1982) · PubMed · Cited by 125
Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol
Hunt, C. M., Watkins, P. B., Saenger, P., Stave, G. M., Barlascini, N., Watlington, C. O., Wright, J. T., & Guzelian, P. S. (1992) · Clinical Pharmacology and Therapeutics · doi:10.1038/clpt.1992.3 · Cited by 118
Statistical Methods for Engineers and Scientists.
Jones, B. C., Bethea, R. M., Duran, B. S., & Boullion, T. L. (1985) · Journal of the Royal Statistical Society Series A (General) · doi:10.2307/2981904 · Cited by 109
Nattel, S., Ranger, S., Talajic, M. R., Lemery, R., & Roy, D. (1990) · The American Journal of Medicine · doi:10.1016/0002-9343(90)90305-w · Cited by 104
Danan, G., Descatoire, V, & Pessayre, D. (1981) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)32700-x · Cited by 98
Cited by
Drug-induced prolongation of the QT interval
Roden, D. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032426 · Cited by 1,965
REDFERN, W., CARLSSON, L., DAVIS, A., LYNCH, W., MACKENZIE, I., PALETHORPE, S., SIEGL, P., STRANG, I., SULLIVAN, A., & WALLIS, R. (2003) · Cardiovascular Research · doi:10.1016/s0008-6363(02)00846-5 · Cited by 1,532
Rendic, S., & Carlo, F. J. D. (1997) · Drug Metabolism Reviews · doi:10.3109/03602539709037591 · Cited by 949
Dresser, G. K., Spence, J. D., & Bailey, D. G. (2000) · Clinical Pharmacokinetics · doi:10.2165/00003088-200038010-00003 · Cited by 908
Inhibition and Induction of Cytochrome P450 and the Clinical Implications
Lin, J. H., & Lu, A. Y. H. (1998) · Clinical Pharmacokinetics · doi:10.2165/00003088-199835050-00003 · Cited by 829
Metadata
- Authors
- Honig, P. K.
- Affiliations
- Uniformed Services University of the Health Sciences (US)
- Corresponding author
- Honig, Peter K.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 1993-03-24
- Volume
- 269
- Issue
- 12
- Pages
- 1513
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1972280475
- Cited by
- 664
- References
- 13
- Citations by year
- 2026: 11 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 4 · 2021: 5 · 2020: 8 · 2019: 5 · 2018: 7 · 2017: 8 · 2016: 19 · 2015: 15 · 2014: 16 · 2013: 13 · 2012: 17
- FWCI
- 44.86
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmacology › Pharmacogenetics and Drug Metabolism
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiac electrophysiology and arrhythmias
- Health Sciences › Medicine › Geriatrics and Gerontology › Pharmaceutical Practices and Patient Outcomes
- Keywords
- terfenadine, ketoconazole, drug interactions, QT prolongation, pharmacokinetics, drug accumulation, antifungal agents, antihistamines
- MeSH terms
- Adult, Drug Interactions, Electrocardiography, Female, Heart, Humans, Ketoconazole, Male, Prospective Studies, Terfenadine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences. https://app.cochat.ai/papers/10.1001/jama.1993.03500120051025
- The paper
- Honig, P. K. (1993). Terfenadine-Ketoconazole Interaction: Pharmacokinetic and Electrocardiographic Consequences. JAMA. https://doi.org/10.1001/jama.1993.03500120051025
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.